Skip to content
Open access

Bepirovirsen: The first antisense oligonucleotide approved to achieve a functional cure for chronic hepatitis B.

Sep 2026 · Drug Discoveries & Therapeutics · Vol 20, pp. 397-399 · 0 citations · 6 references
Medicine

TL;DR

Bepirovirsen is an antisense oligonucleotide that targets conserved HBV RNA sequences, promotes RNase H1-mediated RNA degradation, and reduces viral antigen expression and replication and its overall safety profile was acceptable.

Abstract

Chronic hepatitis B (CHB) remains a major global health burden despite the availability of potent nucleos(t)ide analogue (NA) therapy. Although NAs effectively suppress hepatitis B virus (HBV) DNA replication and reduce the risks of cirrhosis and hepatocellular carcinoma, they have limited effects on covalently closed circular DNA and hepatitis B surface antigen (HBsAg) production, and most patients require prolonged treatment. Bepirovirsen is an antisense oligonucleotide that targets conserved HBV RNA sequences, promotes RNase H1-mediated RNA degradation, and reduces viral antigen expression and replication. In August 2026, Japan approved bepirovirsen (Hibsago) for selected adults with chronic HBV infection receiving NA therapy, representing its first global regulatory approval. Approval was supported by the phase III B-Well 1 and B-Well 2 trials, in which a functional cure after treatment withdrawal was achieved in 20% and 19% of bepirovirsen-treated patients, respectively, versus 0% with a placebo. Response rates were higher among patients with lower baseline HBsAg levels. The overall safety profile was acceptable; however, elevated alanine aminotransferase levels were observed in 6% of bepirovirsen-treated participants. Ongoing studies will further define long-term durability, broader applicability, and optimal treatment strategies.

Read PDF

Similar papers

Review Open access Oct 2026

Oligonucleotide and RNA-targeted therapeutics for chronic hepatitis B: Antigen reduction, delivery, and functional cure strategies

Chronic hepatitis B (CHB) remains difficult to cure because nucleos(t)ide analogs suppress hepatitis B virus (HBV) replication but do not eliminate covalently closed circular DNA (cccDNA) or integrated HBV DNA, which sustain viral RNA and hepatitis B surface antigen (HBsAg) production. RNA-targeted therapeutics, includ...

Xing-Chen Meng, Faisal Mahmood, Hui Li et al. · 0 citations
Review Oct 2026

Evaluating the potential of treatment options for chronic hepatitis B.

The spectrum of established and emerging treatment options for CHB is evaluated, organized around quantitative HBsAg (qHBsAg) as the axis for selecting and sequencing therapy, organized around quantitative HBsAg (qHBsAg) as the axis for selecting and sequencing therapy.

Shang-Chin Huang, J. Kao · 1 citation
Review Open access Oct 2026

Therapeutic advances in chronic hepatitis B and Delta: where are we now and where are we headed?

Chronic hepatitis B (HBV) and delta (HDV) infections remain major global health challenges. Nucleos(t)ide analogues (NUCs) and bulevirtide, a recently approved entry inhibitor, effectively suppress HBV and HDV replication, respectively, thereby reducing the risk of liver-related complications. However, they rarely indu...

A. Pocurull, S. Battistella, Xavier Forns et al. · 0 citations
Review Open access Oct 2026

Clinical Prospect of Novel Therapies for Functional Cure in Chronic Hepatitis B.

RNA-targeting therapies and combination regimens offer promising approaches in attaining functional cure in CHB, with bepirovirsen (an unconjugated antisense oligonucleotide) standing out as the only agent completed in Phase III study showing efficacious results.

K. Ho, R. Hui, L. Mak et al. · 0 citations
Nov 2026

Discovery of XT1061, a HBV Capsid Assembly Modulator, as a Promising Therapeutic Candidate for Clinical Treatment of HBV Infection

Hepatitis B virus (HBV) persists as a major unresolved infectious disease. Patients typically require lifelong administration of nucleos(t)ide analogs (NAs) or interferons but seldom achieve functional cure. Recent studies indicate that HBV core assembly modulators (CAMs), when combined with NAs and interferons, can...

Wei-Bo Guo, Cheng-Hao Wang, Chi Zhang et al. · 0 citations
Open access Oct 2026

Sustained hepatitis D virus-ribonucleic acid negativity after self-discontinuation of short-term bulevirtide therapy: a case report

Chronic hepatitis D virus (HDV) infection represents the most severe form of viral hepatitis and is associated with accelerated progression to cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Bulevirtide (BLV), an entry inhibitor targeting the NTCP receptor, has recently emerged as the standard tr...

G. Massobrio, A. Limongelli, L. Nicolini et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.